5 March 2025
Latham & Watkins Advises Callio Therapeutics on US$187 Million Series A Financing and Concurrent Exclusive License From Hummingbird Bioscience
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matt Bush Lead | Latham & Watkins LLP | Partner | corporate | San Diego |
| Cheston Larson Lead | Latham & Watkins LLP | Partner | corporate | San Diego |
| Chris Hazuka Lead | Latham & Watkins LLP | Partner | Not stated | San Diego |
| Evan Youngstrom | Latham & Watkins LLP | Counsel | corporate | San Diego |
| Alex Stuart-Lovell | Latham & Watkins LLP | Associate | corporate | San Diego |
| Samantha Wang | Latham & Watkins LLP | Associate | corporate | San Diego |
| Rob Yeh | Latham & Watkins LLP | Counsel | Not stated | San Diego |
| Holly Bauer | Latham & Watkins LLP | Partner | compensation and benefits | San Diego |
| Julie Voorhes | Latham & Watkins LLP | Associate | compensation and benefits | San Diego |
| Farhana Sharmeen | Latham & Watkins LLP | Partner | Singapore law | Singapore |
| Zoe Wang | Latham & Watkins LLP | Associate | Singapore law | Singapore |
| Zachary Eddington | Latham & Watkins LLP | Counsel | CFIUS | Washington, D.C. |
Stated terms
- Stated value
- USD 187m (US$187 million)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- Callio Therapeutics (Issuer)
Frazier Life Sciences (Investor)
Jeito Capital (Investor)
Novo Holdings A/S (Investor)
Omega Funds (Investor)
ClavystBio (Investor)
Platanus (Investor)
Norwest (Investor)
Pureos Bioventures (Investor)
SEEDS Capital (Investor)
EDBI (Investor)
Hummingbird Bioscience (Other)